文章：

前列腺癌免疫疗法：从“冷”肿瘤到“热”前景

Immunotherapy in Prostate Cancer: From a “Cold” Tumor to a “Hot” Prospect

原文发布日期：21 March 2025

DOI: 10.3390/cancers17071064

类型: Article

开放获取: 是

英文摘要：

Immunotherapy has shown limited efficacy in prostate cancer, largely due to low tumor immunogenicity, sparse tumor-infiltrating lymphocytes, and a suppressive microenvironment. Recent therapeutic strategies aim to boost immune responses and counteract immunosuppressive factors through interventions such as immune checkpoint inhibitors, immunogenic cell death-inducing therapies, and the targeted blockade of pathways like that of transforming growth factor-β. Vaccine-based approaches, potent immune adjuvants, and engineered chimeric antigen receptor (CAR) T cells are also being investigated to overcome local immune inhibitory signals. Advancements in imaging, multi-omic profiling, and liquid biopsies offer promising avenues for real-time monitoring, better patient selection, and precision treatment. This review provides an overview of the key immunosuppressive features of prostate cancer, current immunotherapeutic modalities, and emerging strategies to transform “cold” tumors into more responsive “hot” targets. By integrating these approaches, we may achieve more durable clinical benefits for patients with advanced or metastatic prostate cancer.

摘要翻译： 

免疫疗法在前列腺癌中的疗效有限，主要归因于肿瘤免疫原性低、肿瘤浸润淋巴细胞稀少以及抑制性微环境。当前的治疗策略旨在通过免疫检查点抑制剂、免疫原性细胞死亡诱导疗法以及靶向阻断转化生长因子-β等通路干预手段，增强免疫反应并抵消免疫抑制因素。基于疫苗的策略、强效免疫佐剂以及工程化嵌合抗原受体T细胞也正在研究中，以克服局部免疫抑制信号。影像学技术、多组学分析和液体活检的进展为实时监测、优化患者选择和精准治疗提供了前景。本综述概述了前列腺癌的关键免疫抑制特征、现有免疫治疗模式以及将“冷”肿瘤转化为更具反应性的“热”靶点的新兴策略。通过整合这些方法，我们有望为晚期或转移性前列腺癌患者实现更持久的临床获益。

原文链接：

Immunotherapy in Prostate Cancer: From a “Cold” Tumor to a “Hot” Prospect